Cipla Launches ‘CIPtest’ Rapid Antigen Detection Test for COVID-19 Diagnosis

▴ Cipla Launches ‘CIPtest’ Rapid Antigen Detection Test for COVID-19 Diagnosis
CIPtest is a reliable high-performing kit that has been validated and approved by ICMR.

Cipla Limited referred to as “Cipla” today announced its partnership with the Premier Medical Corporation Private Limited for commercialization of the rapid antigen test kits for COVID-19 in India. The company will commence supply from this week.

This is Cipla’s second launch in the diagnostics space after Elifast: SARS CoV-2 IgG ELISA Test Kit. In this collaboration, Cipla will be responsible for the marketing and distribution of the Rapid Antigen Detection Test for the qualitative detection of SARS-CoV-2 antigen that will be manufactured by Premier Medical Corporation Private Limited.

The test is a rapid point-of-care nasopharyngeal swab test that directly detects the presence or absence of coronavirus antigen in the patient’s body, generating results within 15-20 minutes. Only authorized labs are permitted by ICMR to conduct rapid antigen testing. The test will be marketed under the brand name ‘CIPtest’.

CIPtest is a reliable high-performing kit that has been validated and approved by ICMR. It is found to have specificity and sensitivity of 98.09% and up to 75 % respectively. The test is not only rapid with a quick turn-around time but also enables easy interpretation of results without the need for any additional instrument. Cipla’s expansive distribution network will help in ensuring the supply of kits across the country.

Tags : #LatestPharmaNewsDec16 #LatestCiplaNewsDec16 #TreatmentforCOVID19 #Teatmentforcoronavirus #COVID19vaccine

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Your Screen Addiction is Shaping Your Child’s Digital Future But Not in a Good WayFebruary 12, 2025
Your Screen Addiction is Shaping Your Child’s Digital Future But Not in a Good WayFebruary 12, 2025
Sarvodaya Hospital Champions Epilepsy Awareness on International Epilepsy DayFebruary 12, 2025
The Oxygen Crisis: Why 5 Billion People Are Struggling to BreatheFebruary 12, 2025
SDGs warrant breakthroughs not breakdowns in development financingFebruary 11, 2025
Emotional and Mental Overload in the AI Era? Meditation is Your CoPilot to Clarity and Calm! says DaajiFebruary 11, 2025
Avvatar Creatine Monohydrate Achieves Trustified Gold CertificationFebruary 11, 2025
Bengaluru’s Pet Healthcare Gets a Boost with Supertails’ Offline ExpansionFebruary 11, 2025
Can Classical Music Shape a Baby’s Heartbeat Before Birth? A New Study Says YesFebruary 11, 2025
What If Learning Was Like Weightlifting? New Science Says It Is!February 11, 2025
Medanta organizes ‘Catwalk for Cancer’ to honour survivors’ strength and resilienceFebruary 10, 2025
Defence Minister, Shri. Rajnath Singh applauds the work done by Aero A2Z for manifesting ‘Make in India’ radar systems February 10, 2025
6 Things Every Young Woman Should Know About Reproductive HealthFebruary 10, 2025
Special Story on Epilepsy DayFebruary 10, 2025
Right wing policies threaten gender equality and health securityFebruary 10, 2025
Lumpy Skin Disease Wiped Out 200,000 Cattle: Can This New Vaccine Be The Ultimate Solution?February 10, 2025
The Future of Healthcare: A Self-Powered Sensor That Tracks Wound Healing Like Never BeforeFebruary 10, 2025
Deworming in Children: A Crucial Step Towards Healthy GrowthFebruary 07, 2025
AI-powered blue-collar hiring platform Vahan.ai secures investment from APAC HR services leader Persol Group amid booming gig economy in India; plans to develop AI recruitment technology to support 8 major Indian languages February 07, 2025
Scars That Never Heal: The Painful Reality of Female Genital MutilationFebruary 06, 2025